Antonin De Fougerolles,John Diener,Emma Hickman,Gregory Hinkle,Stuart Milstein,Anne-Marie Pulichino,Andrew Griffin Sprague
申请号：
US16105522
公开号：
US20180355362A1
申请日:
2018.08.20
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
